Survivorship Data in Prostate Cancer: Where Are We and Where Do We Need To Be?

Autor: Beth Russell, Katharina Beyer, Ailbhe Lawlor, Monique J. Roobol, Lionne D.F. Venderbos, Sebastiaan Remmers, Erik Briers, Sara J. MacLennan, Steven MacLennan, Muhammad Imran Omar, Mieke Van Hemelrijck, Emma Smith, James N'Dow, Karin Plass, Maria Ribal, Nicolas Mottet, Robert Shepherd, Tom Abbott, Ken Mastris, Lisa Moris, Michael Lardas, Thomas Van den Broeck, Peter-Paul Willemse, Nicola Fossati, Karl Pang, Riccardo Campi, Isabella Greco, Mauro Gacci, Sergio Serni, Anders Bjartell, Ragnar Lonnerbro, Alberto Briganti, Daniele Crosti, Roberto Garzonio, Giorgio Gandaglia, Martina Faticoni, Grant office, Chris Bangma, Maria Jongerden, Derya Tilki, Anssi Auvinen, Teemu Murtola, Tapio Visakorpi, Kirsi Talala, Teuvo Tammela, Aino Siltari, Stephane Lejeune, Laurence Colette, Simona Caputova, Delielena Poli, Sophie Byrne, Luz Fialho, Ashley Rowland, Neo Tapela, Nicola Di Flora, Kathi Apostolidis, Valerie Lemair, Bertrand De Meulder, Charles Auffray, Nesrine Taibi, Ayman Hijazy, Albert Saporta, Kai Sun, Shaun Power, Nazanin Zounemat Kermani, Kees van Bochove, Azadeh Tafreshiha, Chiara Bernini, Denis Horgan, Louise Fullwood, Marc Holtorf, Doron Lancet, Gabi Bernstein, Sheela Tripathee, Manfred Wirth, Michael Froehner, Beate Brenner, Angelika Borkowetz, Christian Thomas, Friedemann Horn, Kristin Reiche, Markus Kreuz, Andreas Josefsson, Delila Gasi Tandefelt, Jonas Hugosson, Jack Schalken, Henkjan Huisman, Thomas Hofmarcher, Peter Lindgren, Emelie Andersson, Adam Fridhammar, Monica Tames Grijalva, Susan Evans-Axelsson, Frank Verholen, Jihong Zong, John-Edward Butler-Ransohoff, Todd Williamson, Reg Waldeck, Amanda Bruno, Ekaterina Nevedomskaya, Samuel Fatoba, Niculae Constantinovici, Carl Steinbeisser, Monika Maass, Patrizia Torremante, Emmanuelle Dochy, Federica Pisa, Marc Dietrich Voss, Kishore Papineni, Jing Wang-silvanto, Robert Snijder, Xuewei Wang, Mark Lambrecht, Russ Wolfinger, Sherinne Eid, Soundarya Palanisamy, Samiul Haque, Laurent Antoni, Angela Servan, Katie Pascoe, Paul Robinson, Joana Lencart, Bertrand Jaton, Heidi Turunen, Olavi Kilkku, Pasi Pohjanjousi, Olli Voima, Liina Nevalaita, Keijo Punakivi, Sarah Seager, Shilpa Ratwani, Katarzyna Grzeslak, James Brash, Elaine Longden-Chapman, Danny Burke, Muriel Licour, Sarah Payne, Alan Yong, Flavia Lujan, Sophia Le Mare, Jan Hendrich, Michael Bussmann, Juckeland, Kotik, Christian Reich

Publikováno v: European Urology Open Science, Vol 59, Iss , Pp 27-29 (2024)

Cancer survivorship was recently identified as a prostate cancer (PCa) research priority by PIONEER, a European network of excellence for big data in PCa. Despite being a research priority, cancer survivorship lacks a clear and agreed definition, and

Externí odkaz: https://doaj.org/article/0e8513a8ae754937a693cd11a79baf4a

Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer.

Autor: Fizazi, Karim, Bernard-Tessier, Alice, Roubaud, Guilhem, Utriainen, Tapio, Barthélémy, Philippe, Fléchon, Aude, van der Voet, Johannes, Gravis, Gwenaëlle, Ratta, Raffaele, Jones, Robert, Parikh, Omi, Tanner, Minna, Antonarakis, Emmanuel S., Baldini, Capucine, Peters, Niamh, Garratt, Chris, Ikonen, Tarja, Pohjanjousi, Pasi, Joensuu, Heikki, Cook, Natalie

Publikováno v: NEJM Evidence; Jan2024, Vol. 3 Issue 1, p1-12, 12p

Oral Levosimendan Increases Cerebral Blood Flow Velocities in Patients with a History of Stroke or Transient Ischemic Attack: A Pilot Safety Study

Autor: Matti Kivikko, MD, PhD, Mikko Kuoppamäki, MD, PhD, Lauri Soinne, MD, PhD, Stig Sundberg, PhD, Pasi Pohjanjousi, MSc, Juha Ellmen, PhD, Risto O. Roine, MD, PhD

Publikováno v: Current Therapeutic Research, Vol 77, Iss C, Pp 46-51 (2015)

Background: Intravenous levosimendan is indicated for acute heart failure. The compound has shown promising beneficial effects in ischemic stroke models. Objective: We evaluated the efficacy and safety of oral levosimendan in patients with a history

Externí odkaz: https://doaj.org/article/c17078b80b814610aeb4c2bde7771e9a

How Well do Polygenic Risk Scores Identify Men at High Risk for Prostate Cancer? Systematic Review and Meta-Analysis

Autor: Aino Siltari, Ragnar Lönnerbro, Karl Pang, Kirill Shiranov, Alex Asiimwe, Susan Evans-Axelsson, Billy Franks, Amit Kiran, Teemu J. Murtola, Jack Schalken, Carl Steinbeisser, Anders Bjartell, Anssi Auvinen, J. N’Dow, E.J. Smith, R. Shepherd, M. Ribal, N. Mottet, L. Moris, M. Lardas, P-P. Willemse, G. Gandaglia, R. Campi, Rossella Nicoletti, M. Gacci, A. Briganti, M.M. Ratti, E. Alleva, L. Leardini, E.S. Sisca, R. Bangma, M. Roobol, S. Remmers, D. Tilki, T. Visakorpi, K. Talala, T. Tammela, M. van Hemelrijck, K. Bayer, S. Lejeune, S. Byrne, L. Fialho, P. Palaiologou B. De Meulder, C. Auffray, A. Hijazy, S. Power, N. Zounemat Kermani, K. van Bochove, M. Kalafati, M. Moinat, E. Voss, D. Horgan, L. Fullwood, M. Holtorf, D. Lancet, G. Bernstein, I. Omar, S. MacLennan, S. Maclennan, S. Tripathee, M. Wirth, M. Froehner, B. Brenner, A. Borkowetz, C. Thomas, F. Horn, K. Reiche, M. Kreux, A. Josefsson, D. Gasi Tandefekt, J. Hugosson, H. Huisman, J. Schalken, T. Hofmacher, P. Lindgren, E. Andersson, A. Fridhammar, J. Zong, J-E. Butler-Ransohoff, R. Herrera, M. Maass, P. Torremante, M.D. Voss, Z. Devecseri, T. Abbott, C. Dau, K. Papineni, R. Snijder, M. Lambrecht, R. Wolfinger, S. Rogiers, A. Servan, L. Antoni, K. Pacoe, P. Robinson, B. Jaton, D. Bakkard, H. Turunen, O. Kilkku, P. Pohjanjousi, O. Voima, L. Nevalaita, C. Reich, S. Araujo, E. Longden-Chapman, D. Burke, P. Agapow, S. Derkits, M. Licour, C. McCrea, S. Payne, A. Yong, L. Thompson, S. Le Mare, M Bussmann, D. Kotik

Publikováno v: Clinical Genitourinary Cancer, 21, 2, pp. 316.e1-316.e11
Clinical Genitourinary Cancer, 21, 316.e1-316.e11

Contains fulltext : 291547.pdf (Publisher’s version ) (Open Access) OBJECTIVES: Genome-wide association studies have revealed over 200 genetic susceptibility loci for prostate cancer (PCa). By combining them, polygenic risk scores (PRS) can be gene

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aebe650dd619575ff9d0e1f7617b2c01
https://hdl.handle.net/2066/291547

1420P The pharmacokinetics and the pharmacodynamic effect of ODM-208, an inhibitor of cholesterol side-chain cleavage enzyme (CYP11A1)

Autor: A. Bernard-Tessier, P. Nykanen, T. Utriainen, N. Cook, P. Barthelemy, C. Baldini, N. Peters, T. Ikonen, P. Pohjanjousi, M. Karimaa, J. Malkki, P.T. Toivanen, C. Garratt, K. Fizazi

Publikováno v: Annals of Oncology. 33:S1194

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0be93d94f4dd36952aca320b5cefbdac
https://doi.org/10.1016/j.annonc.2022.07.1906